Medical services disruption escalates with 27 surgeries canceled
[Editorial] Deepfake risks in election
US unveils new major sanctions package for Russia's war against Ukraine, Navalny's death
[Robert J. Fouser] Turning Seoul’s dead streams into parks
Temple that housed book on Hangeul launches Hangeul awareness group
Celltrion, Nippon Kayaku to sell Rituxan biosimilar in JapanBy Sohn Ji-young
Published : April 27, 2017 - 15:36
Celltrion Healthcare, the marketing and sales subsidiary of Celltrion, and Nippon Kayaku have signed a partnership under which the Japanese drugmaker will sell Truxima in Japan.
Rituxan, also known as Mabthera, achieves sales of around 400 billion won ($354 million) in Japan annually. Celltrion and Nippon Kayaku plan to work on securing sufficient clinical trial records in Japan proving the safety and efficacy of Truxima, with aims to seek approval by local regulators. Celltrion has yet to announce an estimated filing timeline.
Nippon Kayaku is also Celltrion’s sales partner in the Japan market for two other biosimilars it has developed -- Remsima referencing Remicade and Herzuma referencing Herceptin.
Meanwhile, Celltrion filed Herzuma for approval by Japan’s Ministry of Health, Labour and Welfare earlier this month. It expects to launch its Herceptin biosimilar in Japan next year.
By Sohn Ji-young (firstname.lastname@example.org)
Major hospitals experience disruptions as junior doctors' walkout enters 5th day
Parents of 7 first to receive W10m for childbirth in Seoul
FM Cho meets with UNESCO chief in Brazil